RECRUITING

Amyloidosis Incidence in High-Risk Cardiac Device Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a new, non-invasive diagnostic avenue for this condition.

Official Title

Histopathological Incidence of Amyloidosis in High-Risk Patients Undergoing Cardiac Device Implantation

Quick Facts

Study Start:2024-01-29
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06186167

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients who are 40 years of age or older
  2. * Patients who are able and willing to provide informed consent
  3. * Patients who are scheduled for CIED implantation within the study period and with clinical lab and imaging features suggestive of cardiac amyloidosis
  1. * Individuals below the age of 40.
  2. * Persons who are unable to consent or who do not consent to participate.
  3. * Patients who have already been diagnosed with cardiac amyloidosis prior to the study

Contacts and Locations

Study Contact

Vasvi Singh, MD
CONTACT
(913) 253-3000
vasvi.singh@hcahealthcare.com
Elizabeth Fulks, MS
CONTACT
(913) 253-3000
elizabeth.fulks@hcahealthcare.com

Principal Investigator

Vasvi Singh, MD
PRINCIPAL_INVESTIGATOR
Midwest Heart & Vascular Specialists

Study Locations (Sites)

Midwest Heart & Vascular Specialists
Overland Park, Kansas, 66211
United States

Collaborators and Investigators

Sponsor: Midwest Heart & Vascular Specialists

  • Vasvi Singh, MD, PRINCIPAL_INVESTIGATOR, Midwest Heart & Vascular Specialists

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-29
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2024-01-29
Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

  • Cardiac Devices
  • Chest Wall Fat Pad Biopsy
  • Cardiac Implantable Electronic Devices

Additional Relevant MeSH Terms

  • Amyloid
  • Cardiac Amyloidosis
  • Amyloidosis Cardiac
  • Systemic Amyloidosis
  • AL Amyloidosis
  • Infiltrative Cardiomyopathy, Amyloid
  • ATTR Amyloidosis Wild Type